LAX.SH
VALIANT LABORATORIES LTD·PHARMACEUTICALS 70.24·Pharmaceuticals & Biotechnology Companies
Price
95.74
+4.45%52W Range
Market Cap
₹519.99 Cr
Traded: ₹3.42 Cr (0.66%) 0.0x
Free Float: ₹119.75 Cr (2.86% of FF traded)
Volume · 60D trend
3.6 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Profit | -- | -- | -- | -- | +3.0% | -- |
| Return | -- | -- | -- | -19.0% | -- | -- |
| ROE | -- | -- | -1.0% | -- | -- | -- |
| Sales | -- | -- | -11.0% | -- | +78.0% | Accelerating |
Quarterly Results
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 115 | 92 | 52 | 46 | 47 | 58 | 35 | 21 | 19 | 31 | 41 | 60 | 51 | 90 | 71 | 88 |
| Expenses | 86 | 87 | 53 | 46 | 44 | 54 | 35 | 28 | 21 | 35 | 47 | 61 | 48 | 81 | 61 | 77 |
| Operating Profit | 29 | 5 | -1 | 0 | 2 | 4 | 1 | -7 | -2 | -5 | -6 | -1 | 4 | 9 | 10 | 11 |
| OPM % | 25.0% | 5.0% | -1.7% | 0.2% | 5.0% | 7.0% | 1.8% | -31.0% | -13.0% | -15.0% | -16.0% | -2.3% | 7.0% | 9.6% | 14.0% | 12.1% |
| Other Income | 1 | 0 | 1 | 1 | 1 | -2 | 2 | 3 | 3 | 2 | 2 | 3 | 2 | 2 | 1 | 1 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 26 | 1 | -3 | 0 | 2 | 1 | 2 | -4 | 0 | -3 | -5 | 1 | 6 | 10 | 10 | 12 |
| Tax % | 19.0% | -68.0% | 136.0% | 25.0% | 26.0% | 26.0% | -44.0% | 21.0% | 219.0% | -52.0% | -31.0% | 25.0% | 26.0% | 20.7% | 25.5% | 25.5% |
| Net Profit | 21 | 2 | -7 | 0 | 2 | 1 | 2 | -5 | -1 | -1 | -4 | 1 | 4 | 8 | 8 | 9 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 3.9 | 0.3 | -1.3 | 0.0 | 0.3 | 0.1 | 0.4 | -0.9 | -0.1 | -0.2 | -0.6 | 0.2 | 1.1 | 1.9 | 3.8 | 4.3 |
| Sales Growth (YoY) | -- | 59.0% | 49.0% | 115.0% | 148.0% | 89.0% | -13.0% | -64.0% | -63.0% | -66.0% | -43.0% | -32.0% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 75.3% | 13.6% | -1.3% | -19.0% | 64.0% | 64.0% | 13.8% | -38.3% | -24.5% | -32.0% | 15.8% | -42.8% | 27.1% | -19.5% | -- |
| OP Growth (YoY) | 1350.0% | 25.0% | -200.0% | 100.0% | 200.0% | 180.0% | 116.7% | -600.0% | -150.0% | -158.0% | -160.4% | -109.4% | -- | -- | -- | -- |
| OP Growth (QoQ) | 480.0% | 600.0% | -- | -100.0% | -50.0% | 300.0% | 114.3% | -250.0% | 60.0% | 16.7% | -500.0% | -125.0% | -53.6% | -13.2% | -7.0% | -- |
| Profit Growth (YoY) | -- | 151.0% | -400.0% | 104.0% | 457.0% | 156.0% | 167.0% | -700.0% | -112.0% | -116.0% | -146.0% | -91.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | 146.2% | -402.3% | 104.6% | 477.8% | 156.5% | 167.2% | -557.9% | -108.6% | -112.0% | -117.1% | -95.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 124.6% | -3350.0% | -88.2% | 161.5% | -69.8% | 149.4% | -866.7% | 60.9% | 64.1% | -436.8% | -81.9% | -45.3% | -48.8% | -11.8% | -- |
| OP Margin | -- | 5.2% | -1.7% | 0.2% | 5.1% | 6.6% | 1.8% | -31.4% | -12.7% | -14.8% | -15.6% | -2.3% | 7.4% | 9.6% | 14.0% | 12.1% |
| Net Margin | -- | 1.9% | -13.5% | 0.4% | 3.9% | 1.2% | 6.7% | -22.1% | -2.7% | -4.0% | -8.6% | 1.3% | 8.3% | 8.7% | 10.8% | 9.8% |
| Material Cost % | -- | 78.0% | 86.0% | 87.0% | 85.0% | 83.0% | 82.0% | 96.0% | 101.0% | 98.0% | 102.0% | 92.0% | 82.0% | 83.0% | 78.0% | 82.0% |
| Employee Cost % | -- | 3.0% | 4.0% | 3.0% | 3.0% | 2.0% | 3.0% | 6.0% | 5.0% | 4.0% | 3.0% | 2.0% | 2.0% | 2.0% | 2.0% | 1.0% |
| P/S | 1.70 | 1.55 | 2.12 | 1.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 32.56 | -- | -- | 60.94 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 1.67 | 1.18 | 1.36 | 0.98 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Copy of Newspaper Publication of Financial Results for the quarter ended June 30, 2026.
Monitoring Agency Report for the quarter ended June 30, 2026
Change in the Registered Office address of the Company, subject to the approval of shareholders and other Statutory Authorities.
Re-appointment of Managing Director, Independent Director and Continuation of Directorship of Non- Executive Director.
Investment in Wholly Owned Subsidiary.
Audited Standalone and Consolidated Financial Results for quarter ended June 30, 2026.
Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
Opening of a new Corporate Office of the Company
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve financial results for ....
for quarter ended June 30, 2026.
Closure of Trading Window for declaration of Financial Results for the quarter ended June 30, 2026.
Please find enclosed
Annual Secretarial Compliance Report for the Financial Year 2025-2026.
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Please find enclosed
Valiant Laboratories Limited announces evaluation of Restructuring options.
Copy of Newspaper Publication of Financial Results for the quarter and year ended 31 March, 2026.
Audited Standalone and Consolidated Financial Results for quarter and year ended March 31, 2026.
Monitoring Agency Report for quarter ended March 31, 2026
Audited Standalone and Consolidated Financial Results for quarter and year ended March 31, 2026.
Appointment of Cost Auditor and Internal Auditor.
Audited Standalone and Consolidated Financial Results for the quarter and year ended March 31, 2026.
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 ,inter alia, to consider and approve financial results for ....
Resignation of Mr. Bhanudas D. Patil as the Senior Management Personnel w.e.f April 22, 2026.
For quarter ended March 31, 2026
Closure of Trading Window for declaration of Financial Results for the quater and year ended 31 March, 2026
Copy of Newspaper Publication of Financial Results for the Quarter and NIne Months ended December 31, 2025.
Audited Standalone and Consolidated Financial Reults for the quarter and nine months ended December 31, 2025.
Monitoring Agency Report for the quarter ended December 31, 2025.
Audited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025.
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2026 ,inter alia, to consider and approve the Financial Results ....
Please find enclosed
Certificate under 74 (5) of SEBI (DP) Regulations, 2018 for the quarter ended December 31, 2025.
Pls find enclosed
Closure of Trading Window for Q3FY2025-26 Financial Results
Audited Standalone and Consolidated Financial Results for the Quarter and Half Year ended September 30, 2025.
Comments of the Board of Directors of the Company on the fine imposed by the Stock Exchanges under the Standard Operating Procedure (SOP) for Non- Compliance with Regulation 29 of SEBI ....
Monitoring Agency Report for the quarter ended September 30, 2025.
Outcome of Board Meeting dated November 11, 2025- Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025.
Press Release titled "Valiant Advanced Sciences Private Limited, a Wholly owned subsidiary, commences commercial operations at its new state-of-the-art greenfield manufacturing facility ....
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 ,inter alia, to consider and approve the financial results ....
Certificate under 74(5) of SEBI (DP) Regulations , 2018 for the quarter ended September 30, 2025.
Please find enclosed.
Closure of Trading Window for the quarter and half-year ended FY 2025-26.
Scrutinizer''s Report and Voting Results of 4th AGM of Valiant Laboratories Limited.
Change in management.
Proceedings of 4th AGM of Valiant Laboratories limited held through VC/OAVM.
Newspaper Advertisement regarding Completion of Dispatch of Annual Report for FY 2024-25 and Notice of 4th Annual General Meeting to the members of the Company.
Newspaper Advertisement regarding Completion of Dispatch of Annual Report for FY 2024-25 and Notice of 4th Annual General Meeting to the members of the Company.
Letter to shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015